Evolus Inc.

8.10+0.1900+2.40%Vol 462.63K1Y Perf 118.58%
Sep 15th, 2021 16:00 DELAYED
BID8.08 ASK8.10
Open7.88 Previous Close7.91
Pre-Market- After-Market-
 - -%  - -
Target Price
17.14 
Analyst Rating
Strong Buy 1.25
Potential %
111.61 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     47.14
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
36.13 
Earnings Rating
Strong Sell
Market Cap442.07M 
Earnings Date
4th Nov 2021
Alpha0.04 Standard Deviation0.50
Beta2.28 

Today's Price Range

7.708.21

52W Range

2.8517.38

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.43%
1 Month
-27.68%
3 Months
-31.70%
6 Months
-39.64%
1 Year
118.58%
3 Years
-61.74%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EOLS8.100.19002.40
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
1.60
1.90
0.02
0.22
-19.20
Leverage Ratio 8.70
ProfitabilityValueIndustryS&P 500US Markets
63.00
-163.20
-152.70
-
-
RevenueValueIndustryS&P 500US Markets
76.58M
1.40
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.30-0.31-3.33
Q01 2021-0.580.16127.59
Q04 2020-0.33-0.81-145.45
Q03 2020-0.50-0.3432.00
Q02 2020-0.84-0.6325.00
Q01 2020-0.72-0.5918.06
Q04 2019-0.85-0.4744.71
Q03 2019-1.33-0.9826.32
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.38-40.74Negative
12/2021 QR-0.35-94.44Negative
12/2021 FY-1.50-17.19Negative
12/2022 FY-0.42-2.44Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.38
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume462.63K
Shares Outstanding54.58M
Shares Float37.37M
Trades Count5.14K
Dollar Volume14.49M
Avg. Volume1.00M
Avg. Weekly Volume697.35K
Avg. Monthly Volume565.67K
Avg. Quarterly Volume538.42K

Evolus Inc. (NASDAQ: EOLS) stock closed at 8.1 per share at the end of the most recent trading day (a 2.4% change compared to the prior day closing price) with a volume of 464.03K shares and market capitalization of 442.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.

The one-year performance of Evolus Inc. stock is 118.58%, while year-to-date (YTD) performance is 141.07%. EOLS stock has a five-year performance of %. Its 52-week range is between 2.85 and 17.38, which gives EOLS stock a 52-week price range ratio of 36.13%

Evolus Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 4.17, a price-to-sale (PS) ratio of 5.77, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.01%, a ROC of -92.26% and a ROE of -172.66%. The company’s profit margin is -%, its EBITDA margin is -152.70%, and its revenue ttm is $76.58 Million , which makes it $1.40 revenue per share.

Of the last four earnings reports from Evolus Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Evolus Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.25), with a target price of $17.14, which is +111.61% compared to the current price. The earnings rating for Evolus Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evolus Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 47.07, ATR14 : 0.63, CCI20 : -132.29, Chaikin Money Flow : -0.31, MACD : -0.78, Money Flow Index : 7.80, ROC : -24.51, RSI : 26.46, STOCH (14,3) : 11.17, STOCH RSI : 0.35, UO : 31.72, Williams %R : -88.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evolus Inc. in the last 12-months were: Crystal Muilenburg (Sold 5 362 shares of value $59 944 ), David Moatazedi (Sold 120 518 shares of value $1 312 642 ), Lauren P. Silvernail (Sold 16 992 shares of value $179 909 ), Michael M. Jafar (Sold 2 699 shares of value $20 135 ), Rui Avelar (Sold 16 992 shares of value $179 923 ), Vikram Malik (Sold 93 160 shares of value $971 283 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
1 (11.11 %)
1 (11.11 %)
Summary RatingStrong Buy
1.25
Moderate Buy
1.67
Moderate Buy
1.67

Evolus Inc.

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex. It has also completed the development program for DWP-450 for the treatment of moderate to severe glabellar lines.

CEO: David Moatazedi

Telephone: +1 949 284-4555

Address: 520 Newport Center Drive, Newport Beach 92660, CA, US

Number of employees: 125

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

61%39%

Bearish Bullish

55%45%

News

Stocktwits